HopeStage
Back to overview

Depression studies

Topics
More filters

Depression

Depression involves persistent low mood or loss of interest, often with tiredness and changes in sleep or appetite.

7264studies shown
Showing 1,333-1,344 of 7,264
Drug study icon
TerminatedNCT03643159

A study to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolarity type I, and Major Depressive Disorder

Official study title

A Multicenter, 180-day Pragmatic Clinical Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

This study ended early.

Multiple locations, including Santa Rosa
Depression, Bipolarity, ...Medication studyAges 18–63
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT01670019

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

Official study title

A Randomized, Blinded, Comparison of Asenapine and Placebo as Adjunctive Treatment in Patients With Non-Psychotic Major Depressive Disorder Incompletely Responsive to Antidepressant Monotherapy

This study has finished and is no longer accepting participants.

Multiple locations, including Augusta
Depression, SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Duke University
Drug study icon
CompletedNCT04285515

study Evaluating Lumateperone Monotherapy in the Treatment of Depression in bipolarity or Major Depressive Disorder

What is this study about?

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
Depression, BipolarityMedication studyAges 18–75
Countries
United States, Bulgaria, Russia, + 2 others
Sponsor
Intra-Cellular Therapies, Inc.
Device study icon
UnknownNCT06391723

Clinical, Cognitive and Neural Effects of Potentiation of ECT by rTMS in Treatment-Resistant Depression

Official study title

Clinical, Cognitive and Neural Effect of Potentiation of Electroconvulsive Therapy (ECT) by Repetitive Transcranial Magnetic Stimulation (rTMS) at 10 ECT in Patients With Characterized Pharmacoresistant Depressive Episode

Current recruitment status is unconfirmed.

Location not clearly listed
DepressionDevice studyAges 18–70
Countries
Sponsor
Centre Hospitalier du Rouvray
Drug study icon
CompletedNCT02977299

Comparative Effectiveness Research study for Antidepressant Incomplete and Non-responders With TRD

Official study title

Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)

This study has finished and is no longer accepting participants.

Multiple locations, including Birmingham
DepressionMedication studyAges 18–80
Countries
United States, Canada
Sponsor
Massachusetts General Hospital (Hospital / academic medical center)
Drug study icon
Active Not RecruitingNCT05434156

ELE-101 Safety & Tolerability Study in Healthy Participants and people with Depression

Official study title

A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.

This study is no longer accepting new participants.

Multiple locations, including Liverpool
DepressionMedication studyAges 18–65
Countries
United Kingdom
Sponsor
Eleusis Therapeutics
Drug study icon
CompletedNCT02722967

Exploratory study to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

Official study title

A Multicenter, 8-week, Open-label, Single-Arm Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System by Adult Subjects With Schizophrenia, Major Depressive Disorder, or Bipolar 1 Treated With Oral Aripiprazole

This study has finished and is no longer accepting participants.

Multiple locations, including Granada Hills
Depression, Schizophrenia, ...Medication studyAges 18–65
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Device study icon
CompletedNCT04448327

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

Official study title

Sex-Dependent Impact of Transcutaneous Vagal Nerve Stimulation on the Stress Response Circuitry and Autonomic Dysregulation in Major Depression

This study has finished and is no longer accepting participants.

In Charlestown
DepressionDevice studyAges 50–65
Countries
United States
Sponsor
Massachusetts General Hospital (Hospital / academic medical center)
Biological study icon
CompletedNCT03142919

Lipopolysaccharide (LPS) Challenge in Depression

Official study title

Response to Inflammatory Challenge in Major Depressive Disorder

This study has finished and is no longer accepting participants.

In Tulsa
DepressionPlacebo comparisonAges 18–55
Countries
United States
Sponsor
Laureate Institute for Brain Research, Inc.
Device study icon
WithdrawnNCT04159012

NESBID: Neuro-Stimulation of the Brain in Depression

Official study title

NESBID: Neuro-Stimulation of the Brain in Depression. A Randomized, Controlled Clinical Trial of Transcranial Direct Current Stimulation Augmentation, as Compared to Sham Therapy, in the Treatment of Ultra-resistant Major Depressive Disorder

This study was withdrawn before enrollment.

In Edmonton
DepressionDevice studyAges 18+
Countries
Canada
Sponsor
University of Alberta

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.